Pharmaco - Today Stories

Expansion will create more than 250 additional high-skilled manufacturing jobs at Pfizer’s Kalamazoo site NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The investment will expand the production of active pharmaceutical ingredient (API) and registered starting materials (RSMs) used in the manufacture of nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer’s laboratories, which will create more than 250 additional high-skilled jobs at Pfizer’s Kalamazoo site.…

Cambridge, UK, June 6, 2022 – SMC Ltd., a leading solutions provider in the manufacturing of pharmaceutical and medical devices, announces the opening of Cambridge Pharma, a new business offering pharmaceutical development services, including sterile fill-finish. The new 20,000 sq ft facility, located at the Cambridge Research Park, UK, includes a purpose-built sterile fill-finish facility, a process development laboratory and an analytical laboratory. Services include process development and scale up, sterile fill finish for clinical trials, QC and stability testing and QP release of clinical trials supplies. Chetan N. Patel, Owner and CEO of SMC Group, has a strategic vision for the Company, “We value pharmaceutical partnerships and continue to expand services in development, manufacturi…

GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPSTM technology Supports development of a strong portfolio of innovative vaccines and specialty medicines GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. Pneumo…

Alistair Macdonald to Retire After 20 Years in Variety of Leadership Roles Michael Brooks Named Chief Operating Officer Company Reports First Quarter 2022 Results and Updates Full Year Guidance MORRISVILLE, N.C., April 29, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michelle Keefe as CEO and a member of the Company’s Board of Directors. Keefe, currently President, Medical Affairs and Commercial Solutions, succeeds Alistair Macdonald, who will retire after 20 years at Syneos Health. Macdonald will remain an advisor to Syneos Health through March 2023. Keefe brings more than 30 years of life sciences industry experience to the role. Since joining Syneos Health in 2017, her lead…

Pfizer will provide all its current and future patent-protected medicines and vaccines available in the U.S. or EU on a not-for-profit basis to 45 lower-income countries. Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to commit to join the Accord. Health officials in these countries will help identify and resolve hurdles beyond supply to inform the roll out in all 45 lower-income countries. Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap and help create a healthier world for 1.2 billion people. DAVOS, Switzerland--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today launched ‘An Accord for a Healthier World.’ This groundbreaking initiative aims to provide all of Pfizer’s…

ICON kick starts the first half of 2022 with a string of prestigious industry awards recognising healthcare intelligence work and staff, as independently judged by peers worldwide Dublin, Ireland – 23 May 2022 – ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, has been recognised with a number of prestigious business and industry awards in April 2022, including Company of the Year at the 2021 Business & Finance Irish Business Awards and Pharma Contract Services Company of the Year at the Pharma Industry Awards 2021. This is the second time the healthcare intelligence company has received the prestigious Company of the Year accolade from the Business an…

New Assay for Patient Care and Use in Clinical Trials Could Lead to Expanded Treatment Options for Melanoma BURLINGTON, N.C.--(BUSINESS WIRE)--May 18, 2022-- Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue. LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. The test is available for use in both clinical trials and for the care and treatment of patients. “Our goal is to provide diagnostic solutions that can help guide the clinical application of new cancer treatments, improving the lives of those living with cancer,” Pras…

- AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology - Cugene to complete a Phase 1a study in healthy volunteers and to conduct a Phase 1b study in patients with autoimmune/inflammatory disease during the option period NORTH CHICAGO, Ill. and WALTHAM, Mass., May 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and cancer, today announced an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well…

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration (FDA) as early as the First Quarter of 2023 Conference call and live audio webcast with slide presentation is scheduled for tomorrow, May 16, 2022, at 8:30 a.m., EDT  CELEBRATION, Fla., May 15, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced a definitive agreement with Orphazyme A/S…

Pfizer to commercialize NURTEC® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need Expands Pfizer’s innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyond Biohaven common shareholders will receive $148.50 per Biohaven share in cash, plus 0.5 of a share of a new publicly traded company that retains Biohaven’s non-CGRP pipeline compounds (“New Biohaven”) Pfizer and Biohaven to hold analyst call at 10am ET today NEW YORK & NEW HAVEN, CONN.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® OD…

Arrangement Expands Labcorp’s Services to Patients and Providers in Southern New Jersey BURLINGTON, N.C., and EGG HARBOR TOWNSHIP, N.J.--(BUSINESS WIRE)--May 9, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, and AtlantiCare, the largest health care organization in southern New Jersey, today announced that they have closed a transaction to expand their long-term strategic relationship. Labcorp will acquire select assets from AtlantiCare’s clinical outreach business, which serves the AtlantiCare Physician Group and Affiliated Physicians and their patients across southern New Jersey. The transaction is the latest in a series of new and expanded collaborations between Labcorp and health systems across the country, demonstrating the value that Labcorp brings to improve labor…

INDIANAPOLIS--(BUSINESS WIRE)--Modular Devices Acquisition, LLC (Modular Devices), a leading provider of mobile cath labs and mobile cleanrooms, today announced the acquisition of Cardiac Services Mobile, Inc. (Cardiac Services Mobile), a mobile cath lab company out of Nashville, TN that serves the US markets. The acquisition builds on Modular Devices’ position as the premier provider of mobile cardiac cath, peripheral vascular, electrophysiology (EP) and mobile CT labs for the rapidly growing US mobile imaging market. Modular Devices, based in Indianapolis, IN, is a long-time driver of innovation in the mobile cath lab industry. The company’s imaging division provides a comprehensive fleet of temporary interim cath, IR, EP and CT labs serving the hospital, ambulatory surgery center (ASC)…

Acquisition to strengthen ADVANZ PHARMA’s position as a partner of choice for commercialisation of specialty and hospital pharmaceuticals in Europe Agreement includes ex-U.S. rights to commercialise orphan drug Ocaliva® for PBC, a progressive autoimmune disease affecting the liver, and the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S. LONDON, May 05, 2022 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, has signed an agreement with Intercept Pharmaceuticals, Inc. (“Intercept”) to acquire the majority of Intercept’s subsidiaries and operations in Europe, Canada, and…

Rebranding comes after a series of strategic acquisitions, most recently Pharm-Olam Company’s newly combined services address clinical development and consulting needs of small and mid-sized biotechs New name unites worldwide experienced workforce in its singular mission CARY, N.C., May 3, 2022 – Global biopharmaceutical services leader, CATO SMS, today unveiled its new name, Allucent with bold branding to emphasize the company’s spotlight on serving the specialized needs of small and mid-sized biotech companies. This move follows a three-year series of strategic acquisitions*, most recently of clinical research provider, Pharm-Olam, that doubled the company’s size, strengthened and deepened its capabilities, and expanded its global reach. Now, Allucent is a unified organization with mor…

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors – Gilead to Have Options to License Several Additional NK Cell Engager Programs FOSTER CITY, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. NK cell engagers represent a novel mechanism with the potential to address a broad range of cancers, including potential for activity in checkpoint resistant and refractory tumors, as well as other disease areas such as inflammation. Under the agreement, Gilead will receive an e…

Groundbreaking “Make to Order” Process for Stem Cell Therapy Wins Supply Chain Category Vaccine Facility in Singen, Germany, Wins Pharma 4.0 Category for Applying Digital Technologies in Production Process Recognition Illustrates Takeda’s Patient-Centricity Throughout its Manufacturing and Supply Processes OSAKA, Japan and CAMBRIDGE, Massachusetts, April 26, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards (FOYA). In the Supply Chain category, Takeda was awarded for its implementation of a new patient-focused supply chain for its allogeneic mesenchymal stem cell therapy; and Takeda’s vaccine pro…

Collaboration Combines Labcorp’s Diagnostic Tests with Getlabs At-Home Phlebotomy Services Underscores Labcorp’s Commitment to Offer Consumers Choice, Convenience and Access to Health Care BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 22, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of Getlabs for Labcorp, an innovative health care service that combines Labcorp’s diagnostic tests with Getlabs phlebotomy service to conveniently test consumers in the comfort of their own homes. With the service, individuals can now schedule a home blood draw or specimen collection when it’s convenient for them. Appointments are available through Labcorp.com. Getlabs provides at-home lab appointments performed by its full-time phlebotomists and charges a convenienc…

$44 million facility increases production of single-use bioprocess containers that are critical to the development of new vaccines and therapies OGDEN, Utah, April 20, 2022 - Thermo Fisher Scientific today celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19. The Ogden site…

Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus (RSV) infections and prevent illness through vaccination Expands Pfizer’s innovative anti-infective pipeline and utilizes the company’s R&D, manufacturing and commercialization expertise with the goal of addressing a significant unmet need for RSV treatments NEW YORK & LONDON & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and ReViral Ltd. announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, dev…

Award Celebrates Outstanding Research With a Focus in 2022 on Gastroenterology Winners’ Discoveries Reveal the Power of the Gut Microbiome Recipients Receive Unrestricted $200,000 USD Award OSAKA, Japan, and CAMBRIDGE, Massachusetts, April 5, 2022 –  Takeda (TSE:4502/NYSE:TAK) and the New York Academy of Sciences today announced the winners of the fourth Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in gastroenterology. Each winner receives an unrestricted prize of $200,000 USD. The 2022 Senior Scientist Award winner is Jeffrey Gordon, M.D., Director of the Edison Family Center for Genome Sciences and Systems Biology and Dr. Robert J. Glaser Distinguished University Professor at Washingt…